

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: JERUSSI *et al.*

Application No.: To be assigned (Division of
U.S. Application No. 10/222,815, filed 8/19/02)

Group Art Unit: To be assigned

Filed: Herewith

Examiner: To be assigned

For: DERIVATIVES OF (-)- AND (+)-
VENLAFAXINE AND METHODS OF
PREPARING AND USING THE SAME
(As amended)

Attorney Docket No.: 4821-536-999

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.56, enclosed is a list of forty four (44) references for the Examiner's review and consideration. These references are listed on the enclosed Form PTO-1449 entitled "List of References Cited by Applicant." These references (AA-BR) are listed in reverse-chronological or alphabetical order. Copies of these references, with the exception of references AA, AL, AR and AS, are not enclosed as the copies were submitted in connection with U.S. Application Nos. 10/222,815, 09/409,889 and 09/450,690, which are the parent and grandparent of this application. Copies will be provided, however, upon the Examiner's request. Copies of references AA, AL, AR and AS are enclosed herewith.


Identification of the foregoing references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since that form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited."

Applicants respectfully request that the Examiner review the references and make them of record by completing and returning the enclosed List of References.

No fee is believed to be due for the submission of this statement as this statement is submitted prior to first office action on the merits. If any fees are required, however, please charge the required fees to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date March 23, 2004



Max Bachrach 45,479
(Reg. No.)
Jones Day
51 Louisiana Avenue, N.W.
Washington, DC 20001-2113
(202) 879-3939

For: Thomas E. Friebe (Reg. No. 29,258)
Jones Day
1155 Avenue of the Americas
New York, NY 10036
(212) 790-9090

Enclosures

LIST OF REFERENCES CITED BY APPLICANT*(Use several sheets if necessary)*

ATTY. DOCKET NO.

4821-536

APPLICATION NO.

To be assigned

APPLICANT

JERUSSI et al.

FILING DATE

Herewith

GROUP

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,673,838	01/2004	Hadfield et al.			
	AB	5,788,986	08/1998	Dodman			
	AC	5,733,566	02/1998	Lewis			
	AD	5,674,533	10/1997	Santus et al.			
	AE	5,639,476	06/1997	Oshlack et al.			
	AF	5,591,767	01/1997	Mohr et al.			
	AG	5,354,556	10/1994	Sparks et al.			
	AH	5,120,548	06/1992	McClelland et al.			
	AI	5,073,543	12/1991	Marshall et al.			
	AJ	5,059,595	10/1991	Le Grazie			
	AK	4,761,501	08/1988	Husbands et al.			
	AL	4,535,186	08/1985	Husbands et al.			
	AM	4,008,719	02/1977	Theeuwes et al.			
	AN	3,916,899	11/1975	Theeuwes et al.			
	AO	3,845,770	11/1974	Theeuwes et al.			
	AP	3,598,123	08/1971	Zaffaroni			
	AQ	3,536,809	10/1970	Applezweig			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AR	WO 00/59851	10/2000	PCT				
	AS	WO 00/32555	06/2000	PCT				
	AT	WO 94/00047	01/1994	PCT				
	AU	WO 94/00114	01/1994	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AV	Askew, A Simple Screening Procedure for Imipramine-Like Antidepressant Agents, Life Sciences No. 10, September 1963, pp. 725-730.
	AW	Castello, R.A., and Mattocks, A.M., J. Pharm. Sci. 51(2):106-108 (1962)
	AX	Handbook of Pharmaceutical Excipients, 2 nd ed., Wade and Willer eds., pp. 257-259 (1994)
	AY	Haskins et al., DMI, Wy-45,030, Wy-45,881 and Ciramadol Inhibit Locus Coeruleus Neuronal Activity, European Journal of Pharmacology, 115 (1985), pp. 139-146.
	AZ	Howell et al., Pharmacokinetics of Venlafaxine and O-desmethylenlafaxine in Laboratory Animals, Xenobiotica, Vol. 24, No. 4, 1994, pp. 315-327.

	BA	Klamerus et al., <i>Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite</i> , J. Clin. Pharmacol., 1992, 32:716-724.
	BB	Moyer et al., <i>Subsensitivity of the Beta-Adrenergic Receptor-Linked Adenylate Cyclase System of Rat Pineal Gland Following Repeated Treatment with Desmethylinipramine and Nialamide</i> , Molecular Pharmacology, 19:187-193, 1981.
	BC	Moyer et al., <i>In Vivo Antidepressant Profiles of the Novel Bicyclic Compounds Wy-45,030 and Wy-45,881</i> , Abstracts Society for Neuroscience, October 1984, pg. 261.
	BD	Muth et al., <i>Biochemical, Neurophysiological, and Behavioral Effects of Wy-45,233 and Other Identified Metabolites of the Antidepressant Venlafaxine</i> , Drug Development Research 23:191-199, 1991.
	BE	Muth et al., <i>Antidepressant Biochemical Profile of the Novel Bicyclic Compounds Wy-45,030, an Ethyl Cyclohexanol Derivative</i> , Biochemical Pharmacology, Vol. 35, No. 24, 1986, pp. 4493-4497.
	BF	Pento, J.T., <i>Drugs of the Future</i> , 13(9):839-840 (1988)
	BG	<i>Physician's Desk Reference</i> , 53 rd Edition, 1999, pp. 3293-3302.
	BH	<i>Remingtons: The Practice of The Science and Pharmacy</i> , 19 th ed., Gennaro, ed., p. 1625 (1995)
	BI	Rudaz, S., et al., <i>Chromatographia</i> , Vol. 50, No. 5/6, 369-372(1999)
	BJ	Sinclair et al., <i>The Tolerability of Venlafaxine</i> , Rev. Contemp. Pharmacother. 1998, 9:333-344.
	BK	Steiner et al., <i>Radioimmunoassay for Cyclic Nucleotides</i> , The Journal of Biological Chemistry, Vol. 247, No. 4, February 25, 1972, pp. 1106-1113.
	BL	Taft et al., <i>Drug Metabolism and Disposition</i> , 25(10): 1215-1218 (1997)
	BM	von Moltke et al., <i>Venlafaxine and Metabolites are Very Weak Inhibitors of Human Cytochrome P450-3A Isoforms</i> , Biol. Psychiatry 1997, 41:377-380.
	BN	von Moltke, L.L., et al., <i>Biol. Psychiatry</i> , 41:377-380 (1997)
	BO	Wang, C. Paul, et al., <i>Chirality</i> , 4(2), 84-90 (1992)
	BP	Wilen et al., <i>Strategies in Optical Resolutions</i> , Tetrahedron, Vol. 33, 1977, pp. 2725 to 2736.
	BQ	Wood et al., <i>The Rapid Preparation of Synaptosomes, Using a Vertical Rotor</i> , Journal of Neurochemistry, Vol. 37, No. 3, September 1981, pp. 795-797.
	BR	Yardley et al., <i>2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity</i> , J. Med. Chem. 1990, Vol. 33, pp. 2899-2905.

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	